# Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

> **NCT00950612** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** GSK's investigational vaccine 692342
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00950612
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-08
- **Primary completion:** 2010-09-30
- **Final completion:** 2010-09-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950612, "Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00950612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*